Sight Sciences, Inc.
NASDAQ:SGHTMedical - Devices
+$0.15 today
- Market cap
- $598.59M
- Beta
- 2.40
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$0.69
Volume 0.34M
Average 0.25M
SGHT Net Income
Bottom-line profit after all expenses, interest, and taxes.
Sight Sciences, Inc.NASDAQ: SGHT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$12.98M, compared with -$14.15M a year earlier. Trailing-twelve-month net income was -$37.25M.
Context
- Net income amounted to 49.7% of revenue in FY2025, down 14.8 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$28.93M (+24.7%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$12.98M-211.9% QoQ
- Last fiscal yearDec 2025
- -$38.43M+25.4% YoY
- LTMMar 2026
- -$37.25M+24.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +8.3% | +23.4% | +15.1 pp |
| 1 year | +25.4% | +24.7% | -0.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (38.43M) USD
- Year-over-year change
- +25.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (38.43M) | +25.4% |
| FY2024 | 2024-12-31 | (51.51M) | +7.3% |
| FY2023 | 2023-12-31 | (55.55M) | +35.6% |
| FY2022 | 2022-12-31 | (86.24M) | -37.0% |
| FY2021 | 2021-12-31 | (62.96M) | — |
Net Income vs competitors
How SGHT compares with its peers on the latest reported figures
- SGHT's LTM Mar 2026 net income of -$37.25M is the 3rd highest of the 7 companies compared; the peer median is -$113.96M.
- Its year-over-year change of +24.6% is the 2nd highest of 6, against a peer median of -50.7%.
- Net income amounts to 46.8% of revenue for SGHT, versus a peer median of 10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $662.33M | -36.7% | +43.0% | 6.1% | |
| LTM Mar 2026 | -$14.96M | +31.0% | — | 5.6% | |
| LTM Mar 2026 | -$37.25M | +24.6% | — | 46.8% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | -$39.87M | — | — | — |
| LTM Jun 2026 | -$188.05M | -102.7% | — | 30.7% | |
| LTM Mar 2026 | -$290.5M | -50.7% | — | 558.2% | |
| LTM Jun 2026 | -$1.1B | -1220.4% | — | 10.1% | |
| Peer median (excluding SGHT) | -$113.96M | -50.7% | +43.0% | 10.1% | |
Competitors are the stored peer set for SGHT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.96M | 71.33M | 81.06M | 79.87M | 77.36M |
| Cost of Revenue | 8.61M | 12.36M | 11.88M | 11.58M | 10.7M |
| Gross Profit | 40.35M | 58.97M | 69.18M | 68.29M | 66.67M |
| Gross Margin | 82.4% | 82.7% | 85.3% | 85.5% | 86.2% |
| Research & Development | 15.63M | 22.86M | 17.56M | 17.99M | 14.61M |
| Selling, General & Admin | 76.19M | 120.07M | 108.89M | 100.83M | 89.16M |
| Operating Expenses | 91.82M | 142.92M | 126.45M | 118.82M | 103.77M |
| Depreciation & Amortization | 1.2M | 1.25M | 614K | 712K | 487K |
| EBITDA | (57.21M) | (80.48M) | (49.42M) | (45.9M) | (32.79M) |
| EBITDA Margin | -116.8% | -112.8% | -61.0% | -57.5% | -42.4% |
| Operating Income | (51.48M) | (83.95M) | (57.27M) | (50.53M) | (37.1M) |
| Operating Margin | -105.2% | -117.7% | -70.7% | -63.3% | -48.0% |
| Interest Income | 0 | 0 | 0 | 0 | 3.97M |
| Interest Expense | 4.37M | 4.47M | 5.41M | 4.66M | 5.14M |
| Other Income / Expenses | (11.29M) | (2.24M) | 1.84M | (739K) | (1.32M) |
| Income Before Tax | (62.77M) | (86.2M) | (55.44M) | (51.27M) | (38.42M) |
| Pre-Tax Margin | -128.2% | -120.8% | -68.4% | -64.2% | -49.7% |
| Income Tax Expense | 188K | 47K | 110K | 236K | 10K |
| Net Income | (62.96M) | (86.24M) | (55.55M) | (51.51M) | (38.43M) |
| Net Margin | -128.6% | -120.9% | -68.5% | -64.5% | -49.7% |
| EPS (Basic) | (1.33) | (1.80) | (1.14) | (1.03) | (0.74) |
| EPS (Diluted) | (1.33) | (1.80) | (1.14) | (1.03) | (0.74) |
| Weighted Avg Shares | 47.5M | 47.85M | 48.63M | 50.13M | 52.15M |
| Weighted Avg Shares (Diluted) | 47.5M | 47.85M | 48.63M | 50.13M | 52.15M |
Sight Sciences, Inc.
NASDAQ:SGHT
Intrinsic Alpha fair value
Locked
Current Price
$10.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.